The FASEB Journal, Vol 8, 440-447, Copyright © 1994 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Regulated expression of human insulin in the liver of transgenic mice corrects diabetic alterations

A Valera, C Fillat, C Costa, J Sabater, J Visa, A Pujol and F Bosch
Department of Biochemistry and Molecular Biology, School of Veterinary Medicine, Autonomous University of Barcelona, Spain.

Transgenic mice expressing the P-enolpyruvate carboxykinase (PEPCK)/human insulin chimeric gene have been obtained as a model to study the feasibility of gene therapy for diabetes. These transgenic animals were healthy and normoglycemic and expressed human insulin in a physiologically regulated manner, mainly in the liver. Streptozotocin- treated transgenic mice had high levels of human insulin immunoreactivity in serum and showed a significant decrease (up to 40%) in glycemia compared with streptozotocin-treated control mice. The expression of genes involved in liver glucose metabolism, such as glucokinase, pyruvate kinase, and PEPCK, which is markedly altered by diabetes, was significantly recovered in transgenic mice treated with streptozotocin. In addition, the activity of both glucokinase and glycogen synthase, and the content of glucose 6-phosphate and glycogen, were normal in the liver, even when transgenic animals were treated with diabetogenic doses of streptozotocin. These results constitute an indication in vivo that diabetes gene therapy is possible, by means of the production of insulin in extrapancreatic tissues.

This article has been cited by other articles:

				Y.-C. Lu, C. Sternini, E. Rozengurt, and E. Zhukova Release of Transgenic Human Insulin from Gastric G Cells: A Novel Approach for the Amelioration of Diabetes Endocrinology, June 1, 2005; 146(6): 2610 - 2619. [Abstract] [Full Text] [PDF]

				E. Riu, A. Mas, T. Ferre, A. Pujol, L. Gros, P. Otaegui, L. Montoliu, and F. Bosch Counteraction of Type 1 Diabetic Alterations by Engineering Skeletal Muscle to Produce Insulin: Insights From Transgenic Mice Diabetes, March 1, 2002; 51(3): 704 - 711. [Abstract] [Full Text] [PDF]

				I. M. Adham, G. Steding, T. Thamm, E. E. Bullesbach, C. Schwabe, I. Paprotta, and W. Engel The Overexpression of the Insl3 in Female Mice Causes Descent of the Ovaries Mol. Endocrinol., February 1, 2002; 16(2): 244 - 252. [Abstract] [Full Text] [PDF]

				P. A. Halban, S. E. Kahn, A. Lernmark, and C. J. Rhodes Gene and Cell-Replacement Therapy in the Treatment of Type 1 Diabetes: How High Must the Standards Be Set? Diabetes, October 1, 2001; 50(10): 2181 - 2191. [Abstract] [Full Text]

				D. K. Short, S. Okada, K. Yamauchi, and J. E. Pessin Adenovirus-mediated transfer of a modified human proinsulin gene reverses hyperglycemia in diabetic mice Am J Physiol Endocrinol Metab, November 1, 1998; 275(5): E748 - E756. [Abstract] [Full Text] [PDF]

				D. Mitanchez, B. Doiron, R. Chen, and A. Kahn Glucose-Stimulated Genes and Prospects of Gene Therapy for Type I Diabetes Endocr. Rev., August 1, 1997; 18(4): 520 - 540. [Abstract] [Full Text] [PDF]

				P. Muzzin, R. C. Eisensmith, K. C. Copeland, and S. L. C. Woo Hepatic Insulin Gene Expression as Treatment for Type 1 Diabetes Mellitus in Rats Mol. Endocrinol., June 1, 1997; 11(6): 833 - 837. [Abstract] [Full Text]